Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 6:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 6,978 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Carcinoma of the Breast Clear all
Not yet recruiting Phase 2 Interventional

Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC

NCT07786428
View directory record Official record
Conditions
Triple-Negative Breast Cancer (TNBC)
Interventions
Pembrolizumab, Paclitaxel (Chemotherapy), Carboplatin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 15, 2026, 6:29 AM EDT
Completed No phase listed Observational

A Real-World Study of Treatment Patterns, Tolerability and Effectiveness of CDK4/6 Inhibition in HR+, HER2-negative Metastatic Breast Cancer Patients

NCT07760714
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 120 Years
Enrollment
945 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 15, 2026, 6:29 AM EDT
Completed No phase listed Observational

Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer

NCT04436393
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Guardant360 test
Diagnostic Test
Lead sponsor
Guardant Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 15, 2026, 6:29 AM EDT
Terminated Not applicable Interventional Results available

Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast

NCT00857714
View directory record Official record
Conditions
Ductal Carcinoma in Situ
Interventions
lapatinib
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 15, 2026, 6:29 AM EDT
Completed Phase 2 Interventional Results available

Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer

NCT03121352
View directory record Official record
Conditions
Metastatic Triple Negative Breast Cancer
Interventions
Carboplatin, Nab-paclitaxel, Pembrolizumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 15, 2026, 6:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

VisR for Noninvasively Interrogating Stromal Collagen Organization as a Breast Cancer Biomarker: Evaluation of Compression in Control Subjects

NCT06547034
View directory record Official record
Conditions
Breast Cancer
Interventions
Ultrasound
Device
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
30 Years to 90 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 15, 2026, 6:29 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Circulating Tumor DNA Exposure in Peripheral Blood

NCT03517332
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer, Melanoma, Ovarian Cancer, Adrenocortical Cancer, Breast Cancer, Other Cancer
Interventions
Not listed
Lead sponsor
Quantgene Inc.
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
5
States / cities
Tucson, Arizona • Celebration, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 15, 2026, 6:29 AM EDT
Not listed No phase listed Observational

Onco4D(TM) Biodynamic Chemotherapy Selection for Breast Cancer Patients

NCT03164863
View directory record Official record
Conditions
Breast Cancer
Interventions
Onco4D Biodynamic Chemotherapy Selection Assay
Diagnostic Test
Lead sponsor
Animated Dynamics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 15, 2026, 6:29 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Studying the Workflow of the American College of Surgeons Geriatric Surgery Program to Improve Clinical Outcomes in Older Adults Undergoing Surgery at the James Cancer Hospital

NCT07606287
View directory record Official record
Conditions
Breast Carcinoma, Malignant Digestive System Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Genitourinary System Neoplasm, Malignant Head and Neck Neoplasm, Malignant Nervous System Neoplasm, Malignant Solid Neoplasm, Malignant Thoracic Neoplasm, Skin Neoplasm, Soft Tissue Neoplasm, Central Nervous System Neoplasm, Endocrine Gland Neoplasms
Interventions
Serious Illness Conversation Program training, ACS Geriatric Surgery Verification Program Implementation
Behavioral · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 15, 2026, 6:29 AM EDT
Not listed Not applicable Interventional

Comparison of Preoperative ABUS and MRI in Newly Diagnosed Breast Cancer Patients

NCT02488187
View directory record Official record
Conditions
Breast Cancer
Interventions
ABUS
Device
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 15, 2026, 6:29 AM EDT
Completed No phase listed Observational

QOL Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser

NCT01803516
View directory record Official record
Conditions
Breast Cancer, Radiation-Induced Telangiectasias
Interventions
questionnaires
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 15, 2026, 6:29 AM EDT
Recruiting Phase 2 Interventional

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

NCT04641247
View directory record Official record
Conditions
Ovarian Neoplasms, Breast Neoplasms
Interventions
Niraparib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
13
States / cities
Tucson, Arizona • Encinitas, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 15, 2026, 6:29 AM EDT
Not listed Not applicable Interventional

A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.

NCT01792726
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Boost to the tumour bed
Radiation
Lead sponsor
University College, London
Other
Eligibility
Female only
Enrollment
1,796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
8
States / cities
Los Angeles, California • Savannah, Georgia • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2019 · Synced Oct 15, 2026, 6:29 AM EDT
Completed Phase 2 Interventional

Study of MDX-010 in Stage IV Breast Cancer

NCT00083278
View directory record Official record
Conditions
Breast Cancer, Adenocarcinoma
Interventions
MDX-010
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
14
States / cities
San Diego, California • Indianapolis, Indiana • Jeffersonville, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 15, 2026, 6:29 AM EDT
Completed Not applicable Interventional

A Low AGE (Advanced Glycation End-product) Dietary Intervention for Breast Cancer Survivors

NCT05265715
View directory record Official record
Conditions
Breast Cancer
Interventions
Low AGE diet, Research blood draw
Other · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 15, 2026, 6:29 AM EDT
Active, not recruiting Phase 1 Interventional

C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)

NCT03635632
View directory record Official record
Conditions
Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma, Relapsed Ewing Sarcoma, Relapsed Rhabdomyosarcoma, Uveal Melanoma, Phyllodes Breast Tumor
Interventions
C7R-GD2.CART cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 74 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2038
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 15, 2026, 6:29 AM EDT
Completed Phase 2 Interventional

ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer

NCT00046514
View directory record Official record
Conditions
Breast Neoplasms, Metastases, Neoplasm
Interventions
ABI-007
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 15, 2026, 6:29 AM EDT
Not listed No phase listed Observational

Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission.

NCT00910884
View directory record Official record
Conditions
Breast Cancer
Interventions
laboratory biomarker analysis, therapeutic dietary intervention
Other · Procedure
Lead sponsor
Brabant Research
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Spokane Valley, Washington
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 15, 2026, 6:29 AM EDT
Active, not recruiting Not applicable Interventional

Group Interventions for Breast Cancer Survivors

NCT01775085
View directory record Official record
Conditions
Breast Cancer Survivor
Interventions
manualized group intervention, standardized, manualized group intervention
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
2
States / cities
Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 15, 2026, 6:29 AM EDT
Recruiting Phase 1 Interventional

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

NCT07517198
View directory record Official record
Conditions
Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin, Non-small Cell Lung Cancer (NSCLC), Prostate Cancer, Ovarian Cancer, Renal Carcinoma (Clear and Non-clear Cell), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatic Cancer, Gastric Cancer, Triple-negative Breast Cancer (TNBC)
Interventions
EXS74539
Drug
Lead sponsor
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Los Angeles, California • Fort Worth, Texas • West Valley City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 15, 2026, 6:29 AM EDT
Completed Phase 1 Interventional

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

NCT01183663
View directory record Official record
Conditions
Advanced Cancers
Interventions
Lenalidomide, Bevacizumab, Sorafenib, Temsirolimus, Oxaliplatin, Leucovorin, 5-fluorouracil
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 15, 2026, 6:29 AM EDT
Terminated Not applicable Interventional

Hypertension Management in Cancer Patients

NCT03919214
View directory record Official record
Conditions
Blood Pressure, Hypertension, Cancer, Cancer, Breast, Cancer of Prostate, CLL, Hematopoietic Malignancy
Interventions
Automated Messaging
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 74 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 15, 2026, 6:29 AM EDT
Completed Phase 1 Interventional

A Safety Study of SGN-LIV1A in Breast Cancer Patients

NCT01969643
View directory record Official record
Conditions
HER2 Positive Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Triple Negative Breast Neoplasms, HER2 Mutations Breast Neoplasms
Interventions
ladiratuzumab vedotin, Trastuzumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
38
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 15, 2026, 6:29 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer

NCT02290834
View directory record Official record
Conditions
Impaired Cognition, Chemo-brain, Breast Cancer
Interventions
Cognitive, functional and subjective assessments, MRI, PET Scan
Other · Device · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Salem, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 15, 2026, 6:29 AM EDT